menu
    • menu

    Company profile for RegeneRx Biopharmaceuticals

    NEW Drugs in Dev: 3
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    RegeneRx Biopharmaceuticals, Inc. (“RegeneRx” or the “Company”) (OTCQB: RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RegeneRx BiopharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15245 Shady Grove Rd # 470, Rockville, MD 20850
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.regenerx.com/home
    Linkedin
    Linkedin
    https://www.linkedin.com/company/regenerx-biopharmaceuticals-inc./
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
    RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations

    15 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenerx-effects-reverse-stock-split-and-terminates-sec-reporting-obligations-301900639.html

    PR NEWSWIRE
    15 Aug 2023
    Share Share
    RegeneRx Receives Stockholder Approval for Reverse Stock Split
    RegeneRx Receives Stockholder Approval for Reverse Stock Split

    07 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenerx-receives-stockholder-approval-for-reverse-stock-split-301895000.html

    PR NEWSWIRE
    07 Aug 2023
    Share Share
    RegeneRx To Extend Consent Solicitation Vote
    RegeneRx To Extend Consent Solicitation Vote

    01 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenerx-to-extend-consent-solicitation-vote-301890689.html

    PR NEWSWIRE
    01 Aug 2023
    Share Share
    First Patient Enrolled into Phase 3 Neurotrophic Keratitis Trial with RGN-259
    First Patient Enrolled into Phase 3 Neurotrophic Keratitis Trial with RGN-259

    13 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-enrolled-into-us-phase-3-neurotrophic-keratitis-clinical-trial-with-rgn-259-301796701.html

    PR NEWSWIRE
    13 Apr 2023
    Share Share
    RegeneRx Issues Letter To Stockholders
    RegeneRx Issues Letter To Stockholders

    11 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/regenerx-issues-letter-to-stockholders-301794921.html

    PR NEWSWIRE
    11 Apr 2023
    Share Share
    Publication of RGN-259 Ph3 Trial Results in Patients Neurotrophic Keratopathy
    Publication of RGN-259 Ph3 Trial Results in Patients Neurotrophic Keratopathy

    03 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/publication-of-rgn-259-phase-3-clinical-trial-results-in-patients-with-neurotrophic-keratopathy-301712318.html

    PR NEWSWIRE
    03 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search